arrow_back Trending Legislation
Share share

Improving Kidney Disease Care and Treatment Access

This act aims to enhance access to kidney disease screenings and education under Medicare. It modifies the dialysis payment system to foster innovation and improve care quality. Furthermore, it expands access to Medigap supplemental insurance for individuals with kidney disease and allows them to retain private insurance longer.
Key points
Expanding kidney disease screenings as part of annual Medicare wellness visits starting 2022.
Increasing access to kidney disease education by allowing more professionals and dialysis facilities to provide it.
Adjusting dialysis payment systems to support new drugs, technologies, and improve service quality.
Ensuring Medigap supplemental insurance access for individuals with kidney disease, regardless of age, from 2022.
Allowing individuals with kidney failure to retain private health insurance for an extended period, from 12 to 42 months.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Chronic Kidney Disease Improvement in Research and Treatment Act of 2021
Print number: HR 4065
Sponsor: Rep. Sewell, Terri A. [D-AL-7]
Process start date: 2021-06-22
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about Improving Kidney Disease Care and Treatment Access

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is HR 4065.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2021-06-22.

What are the main provisions?

Key points include:

  • Expanding kidney disease screenings as part of annual Medicare wellness visits starting 2022.
  • Increasing access to kidney disease education by allowing more professionals and dialysis facilities to provide it.
  • Adjusting dialysis payment systems to support new drugs, technologies, and improve service quality.
  • Ensuring Medigap supplemental insurance access for individuals with kidney disease, regardless of age, from 2022.
  • Allowing individuals with kidney failure to retain private health insurance for an extended period, from 12 to 42 months.

What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Sewell, Terri A. [D-AL-7].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-28.

Analysis and Potential Impact of HR 4065

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health Benefits